leisure time -WSS

leisure time

author：knowledge 2025-09-03 09:34:26 - browse：5

portrait of Jennifer Adair -- coverage from STAT — Jennifer Adair develops scalable, low cost gene therapies at the Fred Hutchinson Cancer Center and helped found the Global Gene Therapy Initiative. Fred Hutch News Service

BALTIMORE — Gene and cell therapies have transformed a handful of devastating disorders in the U.S. and Europe, with more treatments on the way. But those technologies have largely failed to reach most of the world.

These lags are ubiquitous in the current drug development system, where new therapies are approved in wealthy countries and then slowly leak out to low- and middle-income countries, many years later. In the case of gene therapy, that means countries most affected by a disease such as sickle cell may wait decades to access a curative therapy.

For the last few years, a handful of researchers in the U.S. and around the world have tried to find ways of ensuring global access to these technologies. In 2020, they formed the Global Gene Therapy Initiative, with an initial goal of setting up a gene therapy clinical trial for a hemoglobinopathy — such as a disease like sickle cell or beta thalassemia — or HIV in two different low- and middle-income countries by 2024.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： FDA approves first new drug developed for postpartum depression

focus

WSS

Dementia risk linked to living in disadvantaged areas: Study

In rare move, senator releases unverified FBI source report alleging Biden bribe

US jobless claims fall again as labor market continues to flash strength

5 dead in mass shooting on Caribbean island of St. Vincent: Police

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

When a patient nears the end, a feared therapy can comfort

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Cancer drug shortages should be causing more outrage

Bispecific antibodies are next new thing in cancer immunotherapy

How to save PrEP access — and even expand it

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

Trump demands the U.S. pay no more for drugs than other countries … again

Sanders wants to replace patents with prizes for drug inventions

Sports medicine is finally prioritizing gender equality

Judge denies Trump's request for new trial in E. Jean Carroll case

Tori Bowie and the unacceptable rates of Black maternal death

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

focus

Stanford president’s abrupt resignation sparks debate

In rare move, senator releases unverified FBI source report alleging Biden bribe

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

Eli Lilly’s Mounjaro succeeds in second weight

Mystery swirls around US soldier who entered North Korea days ago, officials say

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

leisure time

Wikipedia

focus

focus